Astria Therapeutics, Inc. (ATXS) 10-Year Financial Performance & Capital Metrics

ATXS • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.Show more

Revenue $0
EBITDA -$112M -13.6%
Net Income -$94M -29.3%
EPS (Diluted) -1.68 +30.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -33.52% -6.8%
ROIC -50.3% -8.9%
Debt/Equity 0.02 +1139.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 86.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.38%

ROCE

10Y Avg-92.64%

5Y Avg-88.23%

3Y Avg-35.42%

Latest-39.4%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	500K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	202K	395K	0	119K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-202K	-395K	500K	-119K	0	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.96%	2.27%	-1.24%	1%	-	-	-	-	-
Operating Expenses+	31.66M	35.56M	27.59M	26.37M	27.09M	37.44M	194.98M	53.5M	83.03M	111.56M
OpEx % of Revenue	-	-	55.19%	-	-	-	-	-	-	-
Selling, General & Admin	8.63M	10.11M	8.91M	9.33M	9.07M	11.85M	14.81M	19.73M	25.7M	35.25M
SG&A % of Revenue	-	-	17.82%	-	-	-	-	-	-	-
Research & Development	23.03M	25.45M	18.68M	17.04M	18.32M	25.59M	15.55M	34.26M	57.33M	77.11M
R&D % of Revenue	-	-	37.36%	-	-	-	-	-	-	-
Other Operating Expenses	7K	93K	32K	176K	-303K	0	164.62M	-487K	0	-801K
Operating Income+	-31.66M	-35.56M	-27.09M	-26.37M	-27.09M	-37.44M	-194.98M	-53.5M	-83.03M	-111.56M
Operating Margin %	-	-	-54.19%	-	-	-	-	-	-	-
Operating Income Growth %	-0.46%	-0.12%	0.24%	0.03%	-0.03%	-0.38%	-4.21%	0.73%	-0.55%	-0.34%
EBITDA+	-31.46M	-35.16M	-26.79M	-26.25M	-27.06M	-37.41M	-30.36M	-53.5M	-98.23M	-111.56M
EBITDA Margin %	-	-	-53.58%	-	-	-	-	-	-	-
EBITDA Growth %	-0.47%	-0.12%	0.24%	0.02%	-0.03%	-0.38%	0.19%	-0.76%	-0.84%	-0.14%
D&A (Non-Cash Add-back)	202K	395K	304K	119K	26K	26K	0	0	-15.2M	0
EBIT	-31.66M	-35.22M	-26.9M	-25.77M	-27.09M	-37.44M	-30.36M	-53.5M	-67.83M	-111.56M
Net Interest Income+	0	-595K	-302K	325K	845K	236K	122K	1.72M	10.2M	17.36M
Interest Income	0	242K	160K	425K	845K	236K	122K	1.72M	10.2M	17.36M
Interest Expense	978K	837K	462K	100K	0	0	0	0	0	0
Other Income/Expense	-971K	-502K	-270K	501K	795K	135K	64K	1.67M	10.14M	17.3M
Pretax Income+	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Pretax Margin %	-	-	-54.73%	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Net Margin %	-	-	-54.73%	-	-	-	-	-	-	-
Net Income Growth %	-0.49%	-0.11%	0.24%	0.05%	-0.02%	-0.42%	-4.23%	0.73%	-0.41%	-0.29%
Net Income (Continuing)	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-243.45	-133.31	-75.73	-30.71	-14.06	-12.20	-24.58	-3.55	-2.42	-1.68
EPS Growth %	-0.61%	0.45%	0.43%	0.59%	0.54%	0.13%	-1.01%	0.86%	0.32%	0.31%
EPS (Basic)	-243.45	-133.31	-75.73	-30.71	-14.06	-12.20	-24.58	-3.55	-2.42	-1.68
Diluted Shares Outstanding	134.03K	270.5K	361.36K	842.47K	1.87M	3.06M	8.93M	14.62M	30.12M	56.16M
Basic Shares Outstanding	134.03K	270.5K	361.36K	842.47K	1.87M	3.06M	8.93M	14.62M	30.12M	56.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	63.58M	39.53M	17.46M	38.91M	38.96M	46.33M	127.08M	227.69M	250.94M	334.64M
Cash & Short-Term Investments	62.78M	38.53M	16.37M	37.57M	36.24M	44.93M	125.51M	226.44M	246.53M	328.13M
Cash Only	62.78M	23.6M	16.37M	15.29M	9.9M	24.93M	86.51M	20.52M	175.53M	59.82M
Short-Term Investments	0	14.93M	0	22.28M	26.34M	20M	39M	205.91M	71M	268.31M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1M	1.09M	0	0	0	0	1.25M	4.41M	6.51M
Total Non-Current Assets+	639K	681K	434K	254K	2.82M	1.13M	439K	2.94M	3.72M	7.72M
Property, Plant & Equipment	504K	568K	321K	56K	2.35M	966K	394K	948K	363K	5.11M
Fixed Asset Turnover	-	-	1.56x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	113K	113K	113K	0	0	0	0	0	0	0
Other Non-Current Assets	22K	0	0	198K	473K	165K	45K	2M	3.36M	2.61M
Total Assets+	64.22M	40.21M	17.9M	39.17M	41.78M	47.46M	127.51M	230.63M	254.67M	342.36M
Asset Turnover	-	-	0.03x	-	-	-	-	-	-	-
Asset Growth %	3.02%	-0.37%	-0.55%	1.19%	0.07%	0.14%	1.69%	0.81%	0.1%	0.34%
Total Current Liabilities+	7.81M	8.32M	6.02M	4.17M	5.03M	6.39M	5.2M	9.06M	11.55M	19.13M
Accounts Payable	1.33M	1.41M	773K	1.41M	1.2M	1.54M	1.56M	788K	1.51M	4.32M
Days Payables Outstanding	2.4K	1.3K	-	4.32K	-	-	-	-	-	-
Short-Term Debt	3.17M	3.24M	2.48M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	332K	1.52M	1.36M	2.12M	1.96M	3.37M	4.05M	0
Current Ratio	8.14x	4.75x	2.90x	9.33x	7.74x	7.25x	24.42x	25.13x	21.73x	17.49x
Quick Ratio	8.14x	4.75x	2.90x	9.33x	7.74x	7.25x	24.42x	25.13x	21.73x	17.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.92M	2.8M	89K	56K	1.03M	397K	0	357K	0	3.97M
Long-Term Debt	5.72M	2.48M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.03M	397K	0	357K	0	3.97M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	177K	319K	89K	56K	0	0	0	0	0	0
Total Liabilities	13.73M	11.12M	6.11M	4.23M	6.06M	6.79M	5.2M	9.42M	11.55M	23.1M
Total Debt+	8.95M	5.72M	2.48M	0	2.25M	1.05M	365K	939K	329K	5.35M
Net Debt	-53.83M	-17.87M	-13.89M	-15.29M	-7.65M	-23.88M	-86.14M	-19.59M	-175.2M	-54.47M
Debt / Equity	0.18x	0.20x	0.21x	-	0.06x	0.03x	0.00x	0.00x	0.00x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-32.37x	-42.48x	-58.65x	-263.71x	-	-	-	-	-	-
Total Equity+	50.49M	29.09M	11.79M	34.94M	35.72M	40.67M	122.31M	221.22M	243.12M	319.26M
Equity Growth %	1.69%	-0.42%	-0.59%	1.96%	0.02%	0.14%	2.01%	0.81%	0.1%	0.31%
Book Value per Share	376.72	107.53	32.63	41.48	19.14	13.30	13.70	15.13	8.07	5.68
Total Shareholders' Equity	50.49M	29.09M	11.79M	34.94M	35.72M	40.67M	122.31M	221.22M	243.12M	319.26M
Common Stock	15K	19K	24K	7K	12K	4K	13K	28K	41K	57K
Retained Earnings	-108.01M	-144.07M	-171.43M	-197.3M	-223.6M	-260.9M	-455.81M	-507.64M	-580.53M	-674.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-64.22M	-4K	0	-4K	0	0	0	-79K	0	163K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.79M	-32.86M	-26.84M	-23.46M	-26.57M	-32.48M	-30.15M	-43.53M	-68.44M	-81.21M
Operating CF Margin %	-	-	-53.67%	-	-	-	-	-	-	-
Operating CF Growth %	-0.46%	-0.1%	0.18%	0.13%	-0.13%	-0.22%	0.07%	-0.44%	-0.57%	-0.19%
Net Income	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Depreciation & Amortization	202K	395K	304K	119K	26K	0	0	0	0	0
Stock-Based Compensation	1.66M	2.16M	2.01M	1.77M	1.51M	1.39M	3.36M	4.55M	6.31M	13.04M
Deferred Taxes	0	96K	-4K	-303K	23K	0	0	0	0	0
Other Non-Cash Items	293K	277K	155K	56K	33K	58K	164.7M	1.1M	545K	-4.54M
Working Capital Changes	684K	274K	-1.93M	762K	-1.87M	3.37M	-3.31M	2.65M	-2.41M	4.54M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	196K	77K	-632K	662K	-211K	347K	-1.97M	-766K	725K	2.81M
Cash from Investing+	-421K	-15.49M	14.88M	-21.91M	-4.08M	6.3M	-12.55M	-167.13M	135.05M	-191.86M
Capital Expenditures	-421K	-459K	-57K	18K	-12K	-33K	-21K	-91K	-25K	-325K
CapEx % of Revenue	-	-	0.11%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	52K	30K	369K	-4.07K	6.33K	0	-167.04K	0	0
Cash from Financing+	78.33M	9.16M	4.73M	44.3M	25.62M	40.86M	104.28M	144.72M	88.4M	157.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	84K	503K	23K	4K	54K	31K	23K	84K	420K	4.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-30.21M	-33.32M	-26.89M	-23.45M	-26.58M	-32.52M	-30.17M	-43.62M	-68.47M	-81.54M
FCF Margin %	-	-	-53.79%	-	-	-	-	-	-	-
FCF Growth %	-0.46%	-0.1%	0.19%	0.13%	-0.13%	-0.22%	0.07%	-0.45%	-0.57%	-0.19%
FCF per Share	-225.42	-123.17	-74.42	-27.83	-14.24	-10.63	-3.38	-2.98	-2.27	-1.45
FCF Conversion (FCF/Net Income)	0.91x	0.91x	0.98x	0.91x	1.01x	0.87x	0.15x	0.84x	0.94x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.62%	-90.63%	-133.88%	-110.71%	-74.42%	-97.66%	-239.19%	-30.18%	-31.4%	-33.52%
Return on Invested Capital (ROIC)	-	-677.55%	-445.92%	-225.39%	-85.14%	-125.18%	-552.31%	-33.75%	-46.21%	-50.3%
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-5472.8%	-	-	-	-	-	-	-
Debt / Equity	0.18x	0.20x	0.21x	-	0.06x	0.03x	0.00x	0.00x	0.00x	0.02x
Interest Coverage	-32.37x	-42.48x	-58.65x	-263.71x	-	-	-	-	-	-
FCF Conversion	0.91x	0.91x	0.98x	0.91x	1.01x	0.87x	0.15x	0.84x	0.94x	0.86x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Astria Therapeutics, Inc. (ATXS) reported $0.7M in revenue for fiscal year 2024.

Astria Therapeutics, Inc. (ATXS) grew revenue by 0.0% over the past year. Growth has been modest.

Astria Therapeutics, Inc. (ATXS) reported a net loss of $124.0M for fiscal year 2024.

Dividend & Returns

Astria Therapeutics, Inc. (ATXS) has a return on equity (ROE) of -33.5%. Negative ROE indicates the company is unprofitable.

Astria Therapeutics, Inc. (ATXS) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Astria Therapeutics, Inc. (ATXS) 10-Year Financial Performance & Capital Metrics

ATXS • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$112M -13.6%
Net Income -$94M -29.3%
EPS (Diluted) -1.68 +30.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -33.52% -6.8%
ROIC -50.3% -8.9%
Debt/Equity 0.02 +1139.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 92 (top 8%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 86.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23.98%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.38%

ROCE

10Y Avg-92.64%

5Y Avg-88.23%

3Y Avg-35.42%

Latest-39.4%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	500K	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	-
Cost of Goods Sold+	202K	395K	0	119K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-202K	-395K	500K	-119K	0	0	0	0	0	0
Gross Margin %	-	-	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.96%	2.27%	-1.24%	1%	-	-	-	-	-
Operating Expenses+	31.66M	35.56M	27.59M	26.37M	27.09M	37.44M	194.98M	53.5M	83.03M	111.56M
OpEx % of Revenue	-	-	55.19%	-	-	-	-	-	-	-
Selling, General & Admin	8.63M	10.11M	8.91M	9.33M	9.07M	11.85M	14.81M	19.73M	25.7M	35.25M
SG&A % of Revenue	-	-	17.82%	-	-	-	-	-	-	-
Research & Development	23.03M	25.45M	18.68M	17.04M	18.32M	25.59M	15.55M	34.26M	57.33M	77.11M
R&D % of Revenue	-	-	37.36%	-	-	-	-	-	-	-
Other Operating Expenses	7K	93K	32K	176K	-303K	0	164.62M	-487K	0	-801K
Operating Income+	-31.66M	-35.56M	-27.09M	-26.37M	-27.09M	-37.44M	-194.98M	-53.5M	-83.03M	-111.56M
Operating Margin %	-	-	-54.19%	-	-	-	-	-	-	-
Operating Income Growth %	-0.46%	-0.12%	0.24%	0.03%	-0.03%	-0.38%	-4.21%	0.73%	-0.55%	-0.34%
EBITDA+	-31.46M	-35.16M	-26.79M	-26.25M	-27.06M	-37.41M	-30.36M	-53.5M	-98.23M	-111.56M
EBITDA Margin %	-	-	-53.58%	-	-	-	-	-	-	-
EBITDA Growth %	-0.47%	-0.12%	0.24%	0.02%	-0.03%	-0.38%	0.19%	-0.76%	-0.84%	-0.14%
D&A (Non-Cash Add-back)	202K	395K	304K	119K	26K	26K	0	0	-15.2M	0
EBIT	-31.66M	-35.22M	-26.9M	-25.77M	-27.09M	-37.44M	-30.36M	-53.5M	-67.83M	-111.56M
Net Interest Income+	0	-595K	-302K	325K	845K	236K	122K	1.72M	10.2M	17.36M
Interest Income	0	242K	160K	425K	845K	236K	122K	1.72M	10.2M	17.36M
Interest Expense	978K	837K	462K	100K	0	0	0	0	0	0
Other Income/Expense	-971K	-502K	-270K	501K	795K	135K	64K	1.67M	10.14M	17.3M
Pretax Income+	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Pretax Margin %	-	-	-54.73%	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Net Margin %	-	-	-54.73%	-	-	-	-	-	-	-
Net Income Growth %	-0.49%	-0.11%	0.24%	0.05%	-0.02%	-0.42%	-4.23%	0.73%	-0.41%	-0.29%
Net Income (Continuing)	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-243.45	-133.31	-75.73	-30.71	-14.06	-12.20	-24.58	-3.55	-2.42	-1.68
EPS Growth %	-0.61%	0.45%	0.43%	0.59%	0.54%	0.13%	-1.01%	0.86%	0.32%	0.31%
EPS (Basic)	-243.45	-133.31	-75.73	-30.71	-14.06	-12.20	-24.58	-3.55	-2.42	-1.68
Diluted Shares Outstanding	134.03K	270.5K	361.36K	842.47K	1.87M	3.06M	8.93M	14.62M	30.12M	56.16M
Basic Shares Outstanding	134.03K	270.5K	361.36K	842.47K	1.87M	3.06M	8.93M	14.62M	30.12M	56.16M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	63.58M	39.53M	17.46M	38.91M	38.96M	46.33M	127.08M	227.69M	250.94M	334.64M
Cash & Short-Term Investments	62.78M	38.53M	16.37M	37.57M	36.24M	44.93M	125.51M	226.44M	246.53M	328.13M
Cash Only	62.78M	23.6M	16.37M	15.29M	9.9M	24.93M	86.51M	20.52M	175.53M	59.82M
Short-Term Investments	0	14.93M	0	22.28M	26.34M	20M	39M	205.91M	71M	268.31M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1M	1.09M	0	0	0	0	1.25M	4.41M	6.51M
Total Non-Current Assets+	639K	681K	434K	254K	2.82M	1.13M	439K	2.94M	3.72M	7.72M
Property, Plant & Equipment	504K	568K	321K	56K	2.35M	966K	394K	948K	363K	5.11M
Fixed Asset Turnover	-	-	1.56x	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	113K	113K	113K	0	0	0	0	0	0	0
Other Non-Current Assets	22K	0	0	198K	473K	165K	45K	2M	3.36M	2.61M
Total Assets+	64.22M	40.21M	17.9M	39.17M	41.78M	47.46M	127.51M	230.63M	254.67M	342.36M
Asset Turnover	-	-	0.03x	-	-	-	-	-	-	-
Asset Growth %	3.02%	-0.37%	-0.55%	1.19%	0.07%	0.14%	1.69%	0.81%	0.1%	0.34%
Total Current Liabilities+	7.81M	8.32M	6.02M	4.17M	5.03M	6.39M	5.2M	9.06M	11.55M	19.13M
Accounts Payable	1.33M	1.41M	773K	1.41M	1.2M	1.54M	1.56M	788K	1.51M	4.32M
Days Payables Outstanding	2.4K	1.3K	-	4.32K	-	-	-	-	-	-
Short-Term Debt	3.17M	3.24M	2.48M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	332K	1.52M	1.36M	2.12M	1.96M	3.37M	4.05M	0
Current Ratio	8.14x	4.75x	2.90x	9.33x	7.74x	7.25x	24.42x	25.13x	21.73x	17.49x
Quick Ratio	8.14x	4.75x	2.90x	9.33x	7.74x	7.25x	24.42x	25.13x	21.73x	17.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5.92M	2.8M	89K	56K	1.03M	397K	0	357K	0	3.97M
Long-Term Debt	5.72M	2.48M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.03M	397K	0	357K	0	3.97M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	177K	319K	89K	56K	0	0	0	0	0	0
Total Liabilities	13.73M	11.12M	6.11M	4.23M	6.06M	6.79M	5.2M	9.42M	11.55M	23.1M
Total Debt+	8.95M	5.72M	2.48M	0	2.25M	1.05M	365K	939K	329K	5.35M
Net Debt	-53.83M	-17.87M	-13.89M	-15.29M	-7.65M	-23.88M	-86.14M	-19.59M	-175.2M	-54.47M
Debt / Equity	0.18x	0.20x	0.21x	-	0.06x	0.03x	0.00x	0.00x	0.00x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-32.37x	-42.48x	-58.65x	-263.71x	-	-	-	-	-	-
Total Equity+	50.49M	29.09M	11.79M	34.94M	35.72M	40.67M	122.31M	221.22M	243.12M	319.26M
Equity Growth %	1.69%	-0.42%	-0.59%	1.96%	0.02%	0.14%	2.01%	0.81%	0.1%	0.31%
Book Value per Share	376.72	107.53	32.63	41.48	19.14	13.30	13.70	15.13	8.07	5.68
Total Shareholders' Equity	50.49M	29.09M	11.79M	34.94M	35.72M	40.67M	122.31M	221.22M	243.12M	319.26M
Common Stock	15K	19K	24K	7K	12K	4K	13K	28K	41K	57K
Retained Earnings	-108.01M	-144.07M	-171.43M	-197.3M	-223.6M	-260.9M	-455.81M	-507.64M	-580.53M	-674.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-64.22M	-4K	0	-4K	0	0	0	-79K	0	163K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-29.79M	-32.86M	-26.84M	-23.46M	-26.57M	-32.48M	-30.15M	-43.53M	-68.44M	-81.21M
Operating CF Margin %	-	-	-53.67%	-	-	-	-	-	-	-
Operating CF Growth %	-0.46%	-0.1%	0.18%	0.13%	-0.13%	-0.22%	0.07%	-0.44%	-0.57%	-0.19%
Net Income	-32.63M	-36.06M	-27.36M	-25.87M	-26.29M	-37.3M	-194.91M	-51.83M	-72.89M	-94.26M
Depreciation & Amortization	202K	395K	304K	119K	26K	0	0	0	0	0
Stock-Based Compensation	1.66M	2.16M	2.01M	1.77M	1.51M	1.39M	3.36M	4.55M	6.31M	13.04M
Deferred Taxes	0	96K	-4K	-303K	23K	0	0	0	0	0
Other Non-Cash Items	293K	277K	155K	56K	33K	58K	164.7M	1.1M	545K	-4.54M
Working Capital Changes	684K	274K	-1.93M	762K	-1.87M	3.37M	-3.31M	2.65M	-2.41M	4.54M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	196K	77K	-632K	662K	-211K	347K	-1.97M	-766K	725K	2.81M
Cash from Investing+	-421K	-15.49M	14.88M	-21.91M	-4.08M	6.3M	-12.55M	-167.13M	135.05M	-191.86M
Capital Expenditures	-421K	-459K	-57K	18K	-12K	-33K	-21K	-91K	-25K	-325K
CapEx % of Revenue	-	-	0.11%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	52K	30K	369K	-4.07K	6.33K	0	-167.04K	0	0
Cash from Financing+	78.33M	9.16M	4.73M	44.3M	25.62M	40.86M	104.28M	144.72M	88.4M	157.2M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	84K	503K	23K	4K	54K	31K	23K	84K	420K	4.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-30.21M	-33.32M	-26.89M	-23.45M	-26.58M	-32.52M	-30.17M	-43.62M	-68.47M	-81.54M
FCF Margin %	-	-	-53.79%	-	-	-	-	-	-	-
FCF Growth %	-0.46%	-0.1%	0.19%	0.13%	-0.13%	-0.22%	0.07%	-0.45%	-0.57%	-0.19%
FCF per Share	-225.42	-123.17	-74.42	-27.83	-14.24	-10.63	-3.38	-2.98	-2.27	-1.45
FCF Conversion (FCF/Net Income)	0.91x	0.91x	0.98x	0.91x	1.01x	0.87x	0.15x	0.84x	0.94x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.62%	-90.63%	-133.88%	-110.71%	-74.42%	-97.66%	-239.19%	-30.18%	-31.4%	-33.52%
Return on Invested Capital (ROIC)	-	-677.55%	-445.92%	-225.39%	-85.14%	-125.18%	-552.31%	-33.75%	-46.21%	-50.3%
Gross Margin	-	-	100%	-	-	-	-	-	-	-
Net Margin	-	-	-5472.8%	-	-	-	-	-	-	-
Debt / Equity	0.18x	0.20x	0.21x	-	0.06x	0.03x	0.00x	0.00x	0.00x	0.02x
Interest Coverage	-32.37x	-42.48x	-58.65x	-263.71x	-	-	-	-	-	-
FCF Conversion	0.91x	0.91x	0.98x	0.91x	1.01x	0.87x	0.15x	0.84x	0.94x	0.86x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Astria Therapeutics, Inc. (ATXS) reported $0.7M in revenue for fiscal year 2024.

Astria Therapeutics, Inc. (ATXS) grew revenue by 0.0% over the past year. Growth has been modest.

Astria Therapeutics, Inc. (ATXS) reported a net loss of $124.0M for fiscal year 2024.

Dividend & Returns

Astria Therapeutics, Inc. (ATXS) has a return on equity (ROE) of -33.5%. Negative ROE indicates the company is unprofitable.

Astria Therapeutics, Inc. (ATXS) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.